Case Study: Navigating 2027 Coverage Options
To see how these rules apply in real life, consider how two different Medicare beneficiaries approach their prescriptions in 2027.
Margaret: Qualifying Through the Bridge Program
Margaret is 68 years old and lives in Ohio. She has a Body Mass Index of 36 and mild osteoarthritis, but she does not have diabetes or heart disease.
Her physician recommends Wegovy to relieve severe joint pressure in her knees. Margaret cannot obtain Wegovy through standard Part D because she lacks an established cardiovascular condition.
Instead, her doctor enrolls her in the Medicare GLP-1 Bridge program. Because her BMI exceeds 35 and she has no standard Part D qualifying conditions, she receives Wegovy for a flat $50 monthly copayment.
Margaret must remember that her $50 monthly copayment does not apply toward her $700 Part D deductible, which she must meet separately when filling generic medications.
Arthur: Qualifying Under Standard Part D
Arthur is 71 years old and manages type 2 diabetes alongside a BMI of 31. His endocrinologist prescribes Ozempic to regulate his blood sugar levels.
Because Arthur has an official type 2 diabetes diagnosis, his standard Part D plan covers Ozempic under regular tier-copayment rules rather than the Bridge program.
Arthur pays his plan’s deductible and monthly copayments. Crucially, every dollar spent on Ozempic counts toward his 2027 out-of-pocket maximum of $2,400.
Once Arthur reaches that $2,400 threshold in mid-summer, his Part D plan covers his Ozempic and all other formulary medications at $0 for the rest of 2027.
